[Federal Register Volume 74, Number 81 (Wednesday, April 29, 2009)]
[Notices]
[Pages 19598-19599]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-9799]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 11, 2009, AMRI 
Rensselaer, Inc., 33 Riverside

[[Page 19599]]

Avenue, Rensselaer, New York 12144, made application by renewal to the 
Drug Enforcement Administration (DEA) as a bulk manufacturer of the 
basic classes of controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................   I
Tetrahydrocannabinols (7370)...............   I
Amphetamine (1100).........................   II
Lisdexamfetamine (1205)....................   II
Methylphenidate (1724).....................   II
Pentobarbital (2270).......................   II
Hydrocodone (9193).........................   II
Meperidine (9230)..........................   II
Dextropropoxyphene, bulk (non-dosage form)    II
 (9273).
Oxymorphone (9652).........................   II
Fentanyl (9801)............................   II
------------------------------------------------------------------------

    The company plans to manufacture bulk controlled substances for use 
in product development and for distribution to its customers.
    In reference to drug code 7360 (Marihuana), the company plans to 
bulk manufacture cannabidiol as a synthetic intermediate. This 
controlled substance will be further synthesized to bulk manufacture a 
synthetic THC (7370). No other activity for this drug code is 
authorized for this registration.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than June 29, 2009.

    Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-9799 Filed 4-28-09; 8:45 am]
BILLING CODE 4410-09-P